These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 9630826

  • 1. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.
    Brynne N, Dalén P, Alván G, Bertilsson L, Gabrielsson J.
    Clin Pharmacol Ther; 1998 May; 63(5):529-39. PubMed ID: 9630826
    [Abstract] [Full Text] [Related]

  • 2. Effect of tolterodine on sleep structure modulated by CYP2D6 genotype.
    Diefenbach K, Jaeger K, Wollny A, Penzel T, Fietze I, Roots I.
    Sleep Med; 2008 Jul; 9(5):579-82. PubMed ID: 17921051
    [Abstract] [Full Text] [Related]

  • 3. Effect of the CYP2D6*10 genotype on tolterodine pharmacokinetics.
    Oishi M, Chiba K, Malhotra B, Suwa T.
    Drug Metab Dispos; 2010 Sep; 38(9):1456-63. PubMed ID: 20530222
    [Abstract] [Full Text] [Related]

  • 4. Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers.
    Malhotra B, Darsey E, Crownover P, Fang J, Glue P.
    Br J Clin Pharmacol; 2011 Aug; 72(2):226-34. PubMed ID: 21352267
    [Abstract] [Full Text] [Related]

  • 5. Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance.
    Brynne N, Svanström C, Aberg-Wistedt A, Hallén B, Bertilsson L.
    Br J Clin Pharmacol; 1999 Oct; 48(4):553-63. PubMed ID: 10583026
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine.
    Olsson B, Szamosi J.
    Clin Pharmacokinet; 2001 Oct; 40(3):227-35. PubMed ID: 11327200
    [Abstract] [Full Text] [Related]

  • 8. CYP2D6 polymorphism is not crucial for the disposition of selegiline.
    Scheinin H, Anttila M, Dahl ML, Karnani H, Nyman L, Taavitsainen P, Pelkonen O, Bertilsson L.
    Clin Pharmacol Ther; 1998 Oct; 64(4):402-11. PubMed ID: 9797797
    [Abstract] [Full Text] [Related]

  • 9. Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes.
    Postlind H, DanielsonA, Lindgren A, Andersson SH.
    Drug Metab Dispos; 1998 Apr; 26(4):289-93. PubMed ID: 9531513
    [Abstract] [Full Text] [Related]

  • 10. Food increases the bioavailability of tolterodine but not effective exposure.
    Olsson B, Brynne N, Johansson C, Arnberg H.
    J Clin Pharmacol; 2001 Mar; 41(3):298-304. PubMed ID: 11269570
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
    Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K, Leeder JS, Phillips MS, Gelfand CA, Johnson JA.
    Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
    [Abstract] [Full Text] [Related]

  • 12. Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity.
    Brynne N, Forslund C, Hallén B, Gustafsson LL, Bertilsson L.
    Br J Clin Pharmacol; 1999 Oct; 48(4):564-72. PubMed ID: 10583027
    [Abstract] [Full Text] [Related]

  • 13. Effect of tolterodine on the anticoagulant actions and pharmacokinetics of single-dose warfarin in healthy volunteers.
    Rahimy M, Hallén B, Narang P.
    Arzneimittelforschung; 2002 Oct; 52(12):890-5. PubMed ID: 12572529
    [Abstract] [Full Text] [Related]

  • 14. Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine.
    Dmochowski R, Chen A, Sathyan G, MacDiarmid S, Gidwani S, Gupta S.
    J Clin Pharmacol; 2005 Aug; 45(8):961-8. PubMed ID: 16027408
    [Abstract] [Full Text] [Related]

  • 15. Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole.
    Brynne N, Böttiger Y, Hallén B, Bertilsson L.
    Br J Clin Pharmacol; 1999 Feb; 47(2):145-50. PubMed ID: 10190648
    [Abstract] [Full Text] [Related]

  • 16. Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice.
    Oki T, Maruyama S, Takagi Y, Yamamura HI, Yamada S.
    Eur J Pharmacol; 2006 Jan 04; 529(1-3):157-63. PubMed ID: 16316647
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Interspecies relationship comparing with human pharmacokinetics.
    Påhlman I, Kankaanranta S, Palmér L.
    Arzneimittelforschung; 2001 Feb 04; 51(2):134-44. PubMed ID: 11258043
    [Abstract] [Full Text] [Related]

  • 18. Effect of HNF4α genetic polymorphism G60D on the pharmacokinetics of CYP2D6 substrate tolterodine in healthy Korean individuals.
    Jiang F, Yeo CW, Lee SS, Oh MK, Ghim JL, Shon JH, Kim HS, Kim EY, Kim DH, Shin JG.
    Pharmacogenet Genomics; 2013 Mar 04; 23(3):175-9. PubMed ID: 23292115
    [Abstract] [Full Text] [Related]

  • 19. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites.
    Chalon SA, Desager JP, Desante KA, Frye RF, Witcher J, Long AJ, Sauer JM, Golnez JL, Smith BP, Thomasson HR, Horsmans Y.
    Clin Pharmacol Ther; 2003 Mar 04; 73(3):178-91. PubMed ID: 12621383
    [Abstract] [Full Text] [Related]

  • 20. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.
    Dilger K, Greiner B, Fromm MF, Hofmann U, Kroemer HK, Eichelbaum M.
    Pharmacogenetics; 1999 Oct 04; 9(5):551-9. PubMed ID: 10591535
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.